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IgAnephropathy (IgAN) is a common cause of chronic kidney
disease and end-stage renal failure, especially in young
people. Due to a wide range of clinical outcomes and
difﬁculty in predicting response to immunosuppression, we
need to understand why and identify which patients with
IgAN will develop progressive renal impairment. A deletion
polymorphism affecting the genes encoding the
complement factor H-related protein (FHR)-1 and FHR-3 is
robustly associated with protection against IgAN. Some FHR
proteins, including FHR-1 and FHR-5, antagonize the ability
of complement factor H (fH), themajor negative regulator of
the complement alternative pathway, to inhibit complement
activation on surfaces, a process termed fH deregulation.
From a large cohort of patients, we demonstrated that
plasma FHR-1 and the FHR-1/fH ratio were elevated in IgAN
and associated with progressive disease. Plasma FHR-1
negatively correlated with eGFR but remained elevated in
patients with IgAN with normal eGFR. Serum FHR5 was
slightly elevated in IgAN but did not correlate with eGFR.
Neither FHR5 levels nor the FHR-5/fH ratio was associated
with progressive disease. However, higher serum FHR-5
levels were associated with a lack of response to
immunosuppression, the presence of endocapillary
hypercellularity, and histology scores of disease severity (the
Oxford Classiﬁcation MEST score). Thus, FHR-1 and FHR-5
have a role in IgAN disease progression.
Kidney International (2017) -, -–-; http://dx.doi.org/10.1016/
j.kint.2017.03.043
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I gA nephropathy (IgAN) is the most common primaryglomerulopathy worldwide and is an important cause ofchronic kidney disease, especially in young people.1
IgAN is associated with a wide range of clinical out-
comes. Although 40% of patients will have reached end-
stage renal disease within 20 years of diagnosis, 20% of
patients will have preserved renal function with only minor
urinary abnormalities.2 IgAN is characterized by dominant
or codominant IgA-containing immune deposits on renal
biopsy.3 The pathophysiology of IgAN associated with
characteristic galactose-deﬁcient IgA1 (gd-IgA1)-contain-
ing immune deposits is considered to be a 4-hit mecha-
nism.4 However, the link between mesangial IgA deposition
and the spectrum of clinical outcomes that are character-
istic of IgAN is poorly understood. Therefore, we are
limited in our ability to both identify patients for whom
immunosuppression therapy is appropriate and develop
novel therapeutic strategies. The current repertoire of
clinical tools available to predict outcome and guide
treatment strategies of IgAN, such as proteinuria or
estimated glomerular ﬁltration rate (eGFR), may reﬂect
progressive glomerular scarring as well as active immu-
nologically driven disease.
Systemic and renal complement activation in IgAN is well
documented. However, the role of complement activation in
IgAN pathogenesis remains poorly deﬁned. Complement C3
accompanies IgA immunostaining in most diagnostic IgAN
biopsies.5 Evidence of complement alternative pathway acti-
vation was identiﬁed in the plasma of 30% to 75% of IgAN
adults6,7 and correlated with proteinuria and the rate of renal
function loss in a cohort of 50 IgAN patients.7 An association
was demonstrated between mesangial C3 deposition,
decreased serum C3 levels, and doubling of serum creatinine
or reaching end-stage renal disease in a cohort of 343 IgAN
patients.8 This demonstrated a link between histology and
serum markers of complement activation in IgAN patho-
genesis. Complement activation by the mannose-binding
lectin (MBL) complement pathway in IgAN has also been
demonstrated. MBL and MBL-associated serine protease
(MASP)-1 were detected in 24% of renal biopsies from IgAN
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patients, but were identiﬁed in less than 3% of biopsies from
patients with other forms of glomerulonephritis.9 Deposited
MBL and MASP-1 were associated with C3b, C3c, and C5b9,
which are markers of alternative and terminal complement
pathway activity.9 Although this study did not show associa-
tions with markers of clinical outcomes, glomerular MBL and
other MBL complement pathway components, including
MASP-1/-3 and MASP-2, were found in 25% of a separate
cohort of 60 IgAN patients, and these ﬁndings correlated with
proteinuria and histologic features of severity.10
The ability of IgA to activate complement in vitro,
predominantly through the alternative pathway, has also been
demonstrated. IgA isolated from pooled human plasma
triggers complement-dependent lysis of, and properdin
deposition on, erythrocytes coated with mouse monoclonal
antihuman IgA.11 Furthermore, a rat model of IgA-mediated
glomerular inﬂammation demonstrated that polymeric but
not monomeric IgA triggered mesangial C3 deposition and
not C4 or C1q deposition.12
Recent genetic studies implicate a role for the complement
factor H related (FHR) proteins in IgAN.13–16 The FHR
proteins may interfere with the regulatory functions of factor
H (fH), the major negative regulator of complement C3
activation.17,18 This process is referred to as fH deregula-
tion.19,20 The deletion polymorphism of the genes coding
FHR-3 and FHR-1 (delCFHR3-1) is associated with protec-
tion from IgAN.13,14,16 A meta-analysis of approximately
20,000 individuals of different ethnicities estimated that the
inheritance of the minor A allele at single-nucleotide poly-
morphism rs6677604, which tags the delCFHR3-1 allele,
reduced the risk of IgAN disease by 26% in heterozygosity
and by 45% in homozygosity.14 Across populations world-
wide, delCFHR3-1 frequency exhibits marked differences in a
pattern inverse to that of IgAN prevalence.14 An association
has also been demonstrated between rs6677604 and histologic
IgAN markers. In Chinese patients with IgAN, the rs6677604-
A allele was associated with reduced mesangial C3 deposition,
high serum fH levels, and low complement C3a levels but was
not associated with clinical outcomes.15 Xie et al. showed an
association of delCFHR3-1 with reduced segmental sclerosis
and tubular atrophy in IgAN.16 Although this was indepen-
dent of eGFR and proteinuria, no other associations with
clinical parameters or outcomes were demonstrated.
By enhancing complement activation in response to
mesangial gd-IgA1-containing immune complexes, we
hypothesized that fH deregulation inﬂuences disease severity
in IgAN. In this study, we assessed circulating fH, FHR-1, and
FHR-5 levels in IgAN patients who were stratiﬁed into
cohorts with stable and progressive disease.
RESULTS
Patient cohort
The patient cohort characteristics are summarized in Table 1.
Using the criteria detailed in the Materials and Methods, 179
patients had progressive IgAN and 89 had stable IgAN. We
had insufﬁcient data to categorize 26 patients as having either
progressive or stable IgAN. The cohort of patients meeting
the criteria for progressive IgAN showed lower eGFR and
higher systolic blood pressure than the stable IgAN cohort
(Table 1). Consistent with previous reports,21–23 the median
serum IgA and gd-IgA1 levels were higher in patients than in
controls (Table 1). The progressive IgAN cohort showed
lower median serum IgA and higher median serum gd-IgA1
levels than stable IgAN (Table 1). Similarly, of the patients
who had received immunosuppression therapy, serum
gd-IgA1 levels were higher in patients with progressive IgAN
than stable IgAN after treatment (0.54 units [AU] vs. 0.44 AU,
P ¼ 0.04, Supplementary Figure S1A). Consistent with these
data, we detected a negative correlation between serum
gd-IgA1 levels and eGFRs at the sampling time point
(Supplementary Figure S1B). The delCFHR3-1 allele is asso-
ciated with protection from IgAN.13 However, we did not
observe any difference in CFHR3 and CFHR1 copy numbers
between patients with stable IgAN and those with progressive
IgAN (Table 1).
Plasma FHR-1 levels and the FHR-1:fH ratio were elevated in
IgAN and were associated with progressive disease
While fH is the major negative regulator of C3 activation via
the complement alternative pathway, FHR-1 is postulated to
act as a positive regulator by antagonizing the effect of fH, a
process termed fH deregulation.17–19,24 To investigate fH
deregulation in IgAN, we measured both plasma fH and FHR-
1 levels. The median plasma FHR-1 level was increased in
IgAN patients compared with that in healthy controls,
whereas the plasma fH level did not differ (Table 1). Notably,
the relative abundance of these proteins differed between
patients and healthy controls, and the FHR-1:fH ratio was
signiﬁcantly increased in IgAN patients (Table 1).
Because the presence of the delCFHR3-1 allele will inﬂu-
ence circulating FHR-1 levels (most clearly the absence of the
protein in delCFHR3-1 homozygotes), we stratiﬁed patients
according to the CFHR1 gene copy number. Patients with 2
copies of the CFHR1 gene had higher FHR-1 levels compared
with genotype-matched healthy controls (Figure 1a). This
difference was not observed in patients with 1 CFHR1 gene
copy number (Figure 1a). However, the FHR-1:fH ratio was
signiﬁcantly higher in patients than in healthy controls,
irrespective of the CFHR1 gene copy number (Figure 1b).
FHR-1 was undetectable in deletion homozygotes (n ¼ 12,
including 9 patients). Plasma fH levels remained similar
between patients and controls when stratiﬁed according to the
CFHR1 gene copy number (Figure 1c). As previously
reported,15,25 fH levels were higher in delCFHR3-1 homozy-
gotes (Figure 1c).
We next examined if FHR-1 levels and the FHR-1:fH ratio
differed between patients with stable IgAN and those with
progressive IgAN. Irrespective of the CFHR1 gene copy
number, compared with patients with stable IgAN, those with
progressive IgAN had signiﬁcantly elevated plasma FHR-1
levels (Figure 1d) and FHR-1:fH ratios (Figure 1e), whereas
fH levels did not differ (Table 1). In addition, the FHR-1:fH
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ratio was elevated in patients who had progressive compared
with stable disease following immunosuppression treatment
(Figure 1f).
Plasma FHR-1 was negatively correlated with eGFR but
remained elevated in IgAN patients with normal eGFR
Given that we observed higher FHR-1 levels in patients with
progressive IgAN, we next determined if FHR-1 levels were
inﬂuenced by renal impairment. We stratiﬁed patients by the
CFHR1 gene copy number and assessed the correlation
between FHR-1 levels and eGFR (Figure 2). We detected a
negative correlation between plasma FHR-1 levels and eGFR
in patients with either 1 (Figure 2a) or 2 (Figure 2b) CFHR1
gene copy number. When we stratiﬁed patients into those
with eGFR of <30 ml/min per 1.73 m2 and those with eGFR
of >60 ml/min per 1.73 m2, FHR-1 levels were signiﬁcantly
higher in those with eGFR of <30 ml/min per 1.73 m2
(Figure 2c and d, 1 and 2 CFHR1 copy numbers, respectively).
To determine if FHR-1 levels were higher in IgAN patients
before the development of renal impairment, we compared
FHR-1 levels between IgAN patients with normal eGFR and
healthy controls (Figure 2e). Higher FHR-1 levels were
observed in patients with 2 CFHR1 gene copy numbers and
normal eGFR than in genotype-matched healthy controls
Table 1 | Cohort characteristics
Variable
IgA nephropathy patients
Healthy controls
(n [ 161)
Entire IgAN
(n [ 294)
Stable IgAN
(n [ 89)
Progressive IgAN
(n [ 179)
Clinical features
Male/Female 195/99 53/36 120/59
Caucasian/Non-Caucasian 244/50 78/11 144/35
Median age (range), yr 48.2 (18–84) 47.5 (18–82) 48.3 (19–84)
Median eGFR, ml/min per 1.73 m2 52.7 (28.7–82.7) 74.8 (47.7–106) 45.8 (17.4–70.9)a
Median urine PCR, mg/mmol 44 (16–117) 39 (13.5–89) 50 (17–144.5)
Median antihypertensive drug
classes per patient
1.6 1.4 1.6
Patients with ACEi/ARB at
enrolment, excluding dialysis
patients, % (n)
73.7 (n ¼ 199) 79.8 (n ¼ 71) 77.3 (n ¼ 109)
Median systolic/diastolic blood
pressure, mm Hg
134 (122–145)/79 (70–88)
(n ¼ 286)
128 (116–140)/77.5 (70–85)
(n ¼ 88)
136 (124–146)b/79 (70–88)
(n ¼ 174)
Median follow-up duration, mo 55.0 (22.5–100.8) 71.4 (22.9–177.6) 50.7 (22.2–91.6)
Reached ESRD, % 34.9 (n ¼ 103) 0 57.5c (n ¼ 103)
History of macroscopic hematuria, % 27.8 (n ¼ 82) 44.9 (n ¼ 40) 20.1c (n ¼ 36)
Diagnosis of Henoch-Schonlein
purpura, %
6.4 (n ¼ 19) 0 8.9c (n ¼ 16)
Laboratory measurements
Median serum IgA, g/l 3.4 (2.9–4) (n ¼ 293) 3.7 (3.2–4.3) (n ¼ 88) 3.3 (2.7–3.8)d (n ¼ 178) 2.8 (2.2–3.2)e (n ¼ 57)
Median serum gd-IgA1, AU 0.50 (0.41–0.58) (n ¼ 293) 0.47 (0.37–0.55) (n ¼ 88) 0.52 (0.42–0.59)f (n ¼ 178) 0.42 (0.33–0.55)g (n ¼ 57)
CFHR1–2 copies/1 copy/no copiesh
n 183/101/9 (n ¼ 293) 58/28/3 111/63/4 (n ¼ 178) 85/45/3 (n ¼ 133)
% 62.4/34.5/3.1 65.9/31.8/3.4 62.4/35.4/2.2 63.9/33.8/2.3
CFHR3–2 copies/1 copy/no copies
n 185/100/8 (n ¼ 293) 59/27/3 112/63/3 (n ¼ 178)
% 63.1/34.1/2.7 67/30.7/3.4 62.9/35.4/1.7
Median plasma FHR-1, mg/ml 126.8 (86.4–158.6) 112.5 (74.7–149.3) 132.0 (88.6–162.8) 94.4 (70.5–119.6)i
Median plasma fH, mg/ml 153.8 (130.6–187.6) 155.1 (137.4–187.8) 150.1 (126.0–186.9) 152.5 (122.9–189.8)
Median plasma FHR-1:fH ratio 0.85 (0.55–1.10) 0.77 (0.46–0.98) 0.89 (0.59–1.16)j 0.68 (0.40–0.86)k
Median serum FHR-5, mg/ml 2.74 (2.07–3.64) 2.80 (2.07–3.49) 2.79 (2.08–4.03) 2.46 (1.79–3.67)l (n ¼ 158)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AU, arbitrary units; CFHR, complement factor H-related; CI, conﬁdence interval; ESRD,
end-stage renal disease; fH, factor H; FHR-1/-5, factor H-related protein 1/5; gd-IgA1, galactose-deﬁcient IgA1; PCR, protein-to-creatinine ratio; no, number.
Values within parentheses represent interquartile range and number analyzed if less than the respective cohort numbers.
aP < 0.0001 versus stable disease.
bP ¼ 0.0014 versus stable disease.
cP < 0.0001 versus stable disease.
dP ¼ 0.0007 versus stable disease.
eP < 0.0001 versus entire IgAN cohort.
fP ¼ 0.01 versus stable disease.
gP ¼ 0.015 versus entire IgAN cohort.
h1 patient had 3 copies of CFHR3 and was excluded from the analysis.
iP < 0.0001 versus entire IgAN cohort (difference between medians, 32.4 mg/ml; 95% CI, 19.9–37.6 mg/ml).
jP ¼ 0.019 versus stable disease (difference between medians, 0.12; 95% CI, 0.02–0.2).
kP < 0.0001 versus entire IgAN cohort (difference between medians, 0.17; 95% CI, 0.12–0.24).
lP ¼ 0.041 versus entire IgAN cohort (difference between medians, 0.28 mg/ml; 95% CI, 0.01–0.48 mg/ml).
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Figure 1 | The plasma factor H-related protein 1 (FHR-1) levels and the FHR-1:factor H (fH) ratio are elevated in IgA nephropathy (IgAN)
and are associated with a progressive disease. (a) The plasma FHR-1 levels, (b) FHR-1:fH ratio, and (c) fH levels in healthy controls (gray
boxes) and IgAN patients (white boxes) stratiﬁed according to the CFHR1 gene copy number. Plasma FHR-1 was undetectable in patients with
0 CFHR1 gene copy number. The plasma FHR-1 levels and FHR-1:fH ratio were signiﬁcantly different (P < 0.001) between individuals with
either 1 or 2 CFHR1 gene copy numbers in both the control and IgAN cohorts. (d) Comparison of plasma FHR-1 levels and (e) FHR-1:fH ratio
between patients with stable (dashed gray boxes) and those with progressive (dashed white boxes) IgAN stratiﬁed according to the CFHR1
gene copy number. (f) Comparison of the FHR-1:fH ratio between patients with stable (dashed gray boxes) and those with progressive
(dashed white boxes) IgAN after immunosuppression therapy. The bar represents the median value, box represents the interquartile range,
and whiskers represent the range of values. P values derived using Mann-Whitney test.
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Figure 2 | Factor H-related protein 1 (FHR-1) is negatively correlated with the estimated glomerular ﬁltration rate (eGFR) but remains
elevated in IgA nephropathy (IgAN) patients with normal eGFR. Correlation between plasma FHR-1 levels and eGFR after logarithmic
transformation in IgAN patients with either 1 (a) or 2 (b) CFHR1 gene copy numbers. P values derived from Spearman’s rank correlation.
Plasma FHR-1 levels in IgAN patients with eGFR of <30 (gray boxes) or >60 (white boxes) ml/min per 1.73 m2 stratiﬁed according to 1 (c) or 2
(d) CFHR1 gene copy number. (e) Comparison of the plasma FHR-1 levels between healthy controls (gray boxes) and IgAN patients with eGFR of
>60 ml/min per 1.73 m2 (white boxes) stratiﬁed according to the CFHR1 gene copy number. The bar represents the median value, box
represents the interquartile range, and whiskers represent the range of values. P values derived from Mann-Whitney test. (f) Paired FHR-1 levels
before (Pre) and after (Post) renal transplantation in a cohort of patients with autosomal dominant polycystic kidney disease (ADPKD)
(gray circles, n ¼ 25) and IgAN (white circles, n ¼ 23). All patients were homozygous for the major allele rs6677604, consistent with 2 CFHR1
gene copy numbers.
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(Figure 2e). This difference was not observed in patients with
1 CFHR1 gene copy number (Figure 2e). We next assessed
FHR-1 levels before and after renal transplantation in patients
with either biopsy-proven IgAN or autosomal dominant
polycystic kidney disease (ADPKD). The cohorts had
comparable pretransplant characteristics (Supplementary
Table S1), and no patients had a clinical diagnosis of
delayed graft function, transplant rejection, or disease recur-
rence at the sampling time. Both groups showed signiﬁcant
reduction in serum FHR-1 levels after renal transplantation
(Figure 2f). Altogether, our data indicate that both the diag-
nosis of IgAN and eGFR are independently associated with
higher FHR-1 levels. Notably, there was no signiﬁcant
correlation between eGFR and plasma fH levels in our IgAN
cohort (Supplementary Figure S1C).
Serum FHR-5 was slightly elevated in IgAN but was not
correlated with eGFR
Abnormalities in FHR-5 have been shown to be associated with
C3 glomerulopathy (C3G), a complement-mediated kidney
disease with phenotypic similarities to IgAN.26,27 In addition,
FHR-5 is associated with fH deregulation in vitro.19 We
measured serum FHR-5 levels in our IgAN cohort. Themedian
FHR-5 level was higher in IgAN patients than in healthy con-
trols (Table 1), but the magnitude of the difference was small.
The median FHR-5 levels were 2.46 and 2.74 mg/ml in the
healthy controls and IgAN patients, respectively (difference
between medians, 0.28 mg/ml, 95% conﬁdence interval,
0.01–0.48 mg/ml). Furthermore, we did not detect any differ-
ence in FHR-5 levels between stable and progressive IgAN
patients (Figure 3a and Table 1). However, patients with
progressive disease following immunosuppression treatment
had signiﬁcantly higher FHR-5 levels than patients who
improved to meet stable IgAN criteria after immunosuppres-
sion (Figure 3a). Unlike FHR-1, we did not ﬁnd an association
between serum FHR-5 levels and eGFR (Figure 3b and c).
Moreover, we found no signiﬁcant difference in the FHR-5:fH
ratio between patients and healthy controls or between
progressive and stable IgAN (Supplementary Figure S2).
Serum FHR-5 levels correlated with histologic markers of
renal injury
To explore the signiﬁcance of the changes in serum FHR-5
levels, we assessed the correlation between FHR-5 levels and
validated markers of histologic injury in IgAN, according to
the Oxford classiﬁcation.28 Serum FHR-5 levels at recruit-
ment were signiﬁcantly higher in patients with endocapillary
hypercellularity score E1 at diagnosis than in those with no
endocapillary hypercellularity (E0) (Figure 4a, right panel).
Serum FHR-5 levels in IgAN patients with (M1) and without
(M0) renal biopsy evidence of mesangial hypercellularity did
not differ (Figure 4a, left panel). The total MEST score is
calculated by adding the scores for mesangial hypercellularity
(M), endocapillary hypercellularity (E), segmental sclerosis
(S), and tubular atrophy (T). Serum FHR-5 levels were higher
in IgAN patients with MEST score of 4 than in those with
MEST score of 1 (Figure 4b). Unlike FHR-5, our data
demonstrated that FHR-1 levels were inﬂuenced by eGFR.
Therefore, we did not consider it valid to assess associations
between histologic markers and plasma FHR-1 levels because
eGFR would differ between the diagnostic renal biopsy and
study plasma in many patients.
DISCUSSION
The mechanism underlying the robust association between
the delCFHR3-1 allele and reduced susceptibility to IgAN is
unclear. While the role of fH as a critical negative regulator of
C3 activation through the complement alternative pathway is
well established, the biological roles of the FHR proteins have,
until recently, been poorly understood.17–19 In fact, the
common occurrence of the complete absence of FHR-1 and
FHR-3 in healthy individuals with the delCFHR3-1 allele in
homozygosity has suggested that these 2 FHR proteins are
biologically redundant. Insights into key roles of FHR-1 and
FHR-3 in diseases have been derived from the association
between delCFHR3-1 alleles and protection from not only
IgAN but also age-related macular degeneration.25 Further-
more, abnormal FHR proteins are associated with familial
cases of C3G, a condition wherein complement-mediated
renal injury is derived from abnormal regulation of alterna-
tive pathway activation.20,26,29–31 In vitro data have shown that
FHR-117 and FHR-519 compete with fH for binding to acti-
vated C3 (termed C3b). Unlike fH, interaction of C3b with
either FHR-1 or FHR-5 allows continued complement acti-
vation, preventing the inhibitory actions of fH, a phenome-
non referred to as fH deregulation. We considered that the
association between delCFHR3-1 alleles and IgAN can be
explained by fH deregulation. We hypothesized that reduced
(or absent) FHR-1 levels result in a reduction or absence of fH
deregulation and consequently less complement-mediated
renal injury.
In this study, we ﬁrst explored the association between
FHR-1 and fH levels in patients with either stable or pro-
gressive IgAN. We found that FHR-1 levels and importantly,
the FHR-1:fH ratio, were higher in IgAN patients than in
healthy controls. These data are replicated in a separate IgAN
cohort (Tortajada A, Gutierrez E, Goicoechea de Jorge E, et al.
Elevated factor H-related 1 and occurrence of factor H
pathogenic variants in IgA nephropathy. Kidney International,
submitted for publication). In addition, irrespective of the
CFHR1 gene copy number, patients with progressive IgAN
had signiﬁcantly elevated plasma FHR1/fH ratios compared
to patients with stable IgAN. These data are consistent with
our hypothesis that reduced fH deregulation is associated
with favorable outcomes in IgAN. We categorized the patient
cohort into those with progressive IgAN and those with stable
IgAN. Our criteria were designed to enable us to identify
patients with immunologically active disease. The criteria
included eGFR loss without additional renal pathology and
histologic features of glomerular inﬂammation, such as the
presence of endocapillary hypercellularity and cellular cres-
cents. Although this inevitably excluded a subset of patients
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(those we could not reliably categorize as either stable or
progressive at study entry), our robust classiﬁcation enabled
us to detect differences in FHR-1 levels and the FHR-1:fH
ratio. Although changes in these parameters correlated with
worse disease outcomes, the levels showed large overlap be-
tween the groups, precluding their use for patient stratiﬁca-
tion. In addition, our cohort included 9 individuals (3 with
stable IgAN, 4 with progressive IgAN, and 2 who did not fulﬁl
the criteria) with delCFHR3-1 allele homozygosity, demon-
strating that even in the complete absence of FHR-1 and
FHR-3, renal injury that requires renal biopsy and hospital
follow-up can occur. This is consistent with previous studies16
and indicates that factors independent of fH deregulation can
drive the disease.
We did not measure FHR-3 levels because of the lack of a
reliable assay. FHR-3 is not clearly associated with fH dereg-
ulation, and its role remains unclear; it can interact with the
meningococcus fH-binding protein and through competition
with fH, inﬂuence the complement-mediated clearance of
meningococcal strains and hence meningococcal disease
severity.32 Through interaction with its ligand C3d, FHR-3
may inﬂuence B-cell regulation through a B-cell receptor
complex (CD19/CD21/CD81), but the association with IgAN
is unclear.33 Notably, despite the interaction with C3d, this
effect was not observed for FHR-1.
We found a negative correlation between eGFR and plasma
FHR-1 levels measured at study recruitment. When patients
with normal eGFR were compared with genotype-matched
healthy controls, patients with 2 CFHR1 gene copy numbers
and normal eGFR had higher FHR-1 levels. Both IgAN
patients and ADPKD patients showed reduced FHR-1 levels
coincidental with increased eGFRs after renal transplantation.
This indicated that the diagnosis of IgAN and eGFR are
independently associated with higher FHR-1 levels. Moreover,
this conclusion is supported by the ﬁndings in a study that
assessed FHR-1 levels in IgAN and polycystic renal disease
(Tortajada A, Gutierrez E, Goicoechea de Jorge E, et al.
Elevated factor H-related 1 and occurrence of factor H
pathogenic variants in IgA nephropathy. Kidney International,
submitted for publication). Although we consider the asso-
ciation to be robust, we currently do not know why FHR-1
increases as eGFR decreases. Nevertheless, this would be
predicted to further enhance fH deregulation and aggravate
disease. It is predicted that this could be applicable to any
glomerular pathology in which there is complement-
mediated injury and that there are more general implica-
tions beyond IgAN. Because FHR-1 levels were inﬂuenced by
eGFR and diagnostic renal biopsy was not coincident with the
timing of the study blood sample in our cohort, we did not
analyze the association between FHR-1 and histologic changes
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Figure 3 | Serum factor H-related protein 5 (FHR-5) levels are
associated with IgA nephropathy (IgAN) severity following
immunosuppression therapy and are not correlated with
estimated glomerular ﬁltration rate (eGFR). (a) Left panel,
Comparison of serum FHR-5 levels between stable (dashed gray
boxes) and progressive (dashed white boxes) IgAN. Right panel,
Comparison of serum FHR-5 between patients with stable (dashed
gray boxes) and those with progressive (dashed white boxes) IgAN
after immunosuppression therapy. (b) Correlation between serum
FHR-5 levels and eGFR in IgAN patients. (c) Serum FHR-5 levels in
=
IgAN patients with eGFR of <30 (gray boxes) or >60 (white boxes)
ml/min per 1.73 m2. The bar represents the median value, box rep-
resents the interquartile range, and whiskers represent the range of
values. P values derived using Mann-Whitney test.
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in the renal biopsy. A prospective study will be required to
clarify the contribution of FHR-1 to histologic changes before
decreases in eGFR.
As published data showed that FHR-5 can mediate fH
deregulation19 and studies indicated the strong association
between FHR-5 mutation and C3G,26,30,31 we measured
serum FHR-5 levels and the FHR-5:fH ratio. Notably, there
are strong phenotypic similarities between familial C3G
associated with FHR-5 mutations and IgAN.27 Despite a
signiﬁcant increase in serum FHR-5 levels between IgAN
patients and healthy controls, the magnitude of the difference
was very small and of doubtful biological signiﬁcance. In
addition, we did not identify any difference in FHR-5 levels
between patients with stable disease and those with progres-
sive disease. However, when we analyzed only patients treated
with immunosuppression therapy, FHR-5 levels were higher
in those with ongoing progressive IgAN. The signiﬁcance of
this is unclear and requires conﬁrmation. Unlike the FHR-
1:fH ratio, we did not detect any correlation between the
FHR-5:fH ratio and disease outcome. Because eGFR did not
inﬂuence the serum FHR-5 levels, we assessed the correlations
between serum FHR-5 levels and validated histologic markers
of renal injury in IgAN. Serum FHR-5 levels were associated
with endocapillary hypercellularity independent of mesangial
hypercellularity, a histologic marker of active inﬂammation.34
They were also associated with higher overall Oxford classi-
ﬁcation of IgAN MEST scores.35 To further understand these
associations, it would be necessary to analyze the pattern and
degree of FHR-5 deposition in renal tissues. In this respect, it
is notable that FHR-5 was detected in association with com-
plement C3 in patients with IgAN. Notably, the association
between FHR-5 and C3 was also observed in membranous
nephropathy, lupus nephritis, and postinfectious nephritis,
indicating that this phenomenon is not speciﬁc to IgAN.36
The limitations of our dataset include the difference in
timing between diagnostic renal biopsy and study sample
collection and the lack of serial blood samples from patients.
Additionally, it would be important to investigate the relative
amounts of C3, fH, FHR-1, and FHR-5 in renal tissues in IgAN.
Current assessment of IgAN patients involves the use of
nonspeciﬁc clinical and histologic markers to identify patients
likely to improve with immunosuppression therapy. However,
the beneﬁt of the currently recommended 6-month cortico-
steroid treatment for persistently proteinuric, noncrescentic
IgAN37 has not been conclusively demonstrated.38 Our data,
together with those of a separate cohort (Tortajada A,
Gutierrez E, Goicoechea de Jorge E, et al. Elevated factor
H-related 1 and occurrence of factor H pathogenic variants in
IgA nephropathy. Kidney International, submitted for publi-
cation), associate circulating FHR-1 levels and the FHR-1:fH
ratio with IgAN severity. Our ﬁndings need corroboration
with histologic data but nevertheless suggest that fH dereg-
ulation contributes to IgAN progression and support further
investigation into this hypothesis. If it can be shown that
complement-mediated kidney injury in IgAN is inﬂuenced by
FHR-1 and mechanistically understood, the modulation of
FHR-1 might be therapeutic in progressive IgAN.
MATERIALS AND METHODS
Study cohort and clinical measurements
The Causes and Predictors of Outcome in IgA Nephropathy study is
a retrospective cohort UK study of patients with biopsy-proven IgAN
ethically approved by the UK National Research Ethics Service
Committee (14/LO/0155). The inclusion criteria were availability of
the renal biopsy report and relevant clinical data. In this study, 334
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Figure 4 | Serum factor H-related protein 5 (FHR-5) levels are
correlated with histologic markers of disease severity in IgA
nephropathy (IgAN). (a) Left panel, Serum FHR-5 levels in IgAN
patients without (M0, gray box) and with (M1, white box) renal biopsy
evidence of mesangial hypercellularity (denoted M). Right panel,
Serum FHR-5 levels in IgAN patients without (E0, gray box) and with
(E1, white box) biopsy evidence of endocapillary hypercellularity
(denoted E). (b) Serum FHR-5 levels in IgAN patients with diagnostic
renal biopsy MEST scores of 1 or less (gray box) or at least 4 (white
box). The bar represents the median value, box represents the
interquartile range, and whiskers represent the range of values.
P values derived using Mann-Whitney test.
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patients were recruited, and after excluding 40 patients, 294 were
analyzed. The reasons for exclusion were alternative diagnosis
(n ¼ 4), no biopsy immunostaining completed (n ¼ 5), no biopsy
report available (n ¼ 3), and no creatinine measurement at
enrollment (n ¼ 28).
Progressive disease was considered if at least one of the following
criteria was present: (i) progression to end-stage renal disease
without histologic evidence of a second pathology causing renal
impairment, (ii) renal biopsy evidence of endocapillary hyper-
cellularity, (iii) renal biopsy evidence of cellular and/or ﬁbrocellular
crescents; (iv) treatment with immunosuppressants (including
corticosteroids) for native IgAN, (v) clinical Henoch-Schonlein
purpura, unless spontaneous resolution and >20 years of follow-
up with “stable” criteria, (vi) 50% loss of eGFR or an average
annual eGFR loss of >5 ml/min per 1.73 m2 without evidence of a
second pathology causing renal impairment. Stable disease was
considered if none of the criteria for progressive IgAN were met and
if all of the following criteria were met: (i) urine protein-to-
creatinine ratio of <100 units or daily proteinuria of <1 g/24 h,
(ii) combined Oxford classiﬁcation MEST score of <3, and (iii) an
average annual eGFR loss of <3 ml/min per 1.73 m2.
All patients in the transplantation cohorts received a renal
transplant and underwent clinical follow-up at Imperial College
Healthcare NHS Trust. They received posttransplant immunosup-
pression therapy and clinical care as per local guidelines. All ADPKD
patients had a radiological diagnosis. All transplant patients provided
consent for the storage of serum and plasma samples that were
surplus to clinical diagnostic requirements and their subsequent use
for research. Blood samples were obtained within 4 weeks before and
between 12 and 16 weeks after transplantation. Two transplant
ADPKD patients, both of whom had the AA rs6677604 single-
nucleotide polymorphism genotype, had undetectable FHR-1 levels
before and after transplantation.
Healthy control samples were obtained from healthy volunteer
donors and from members of the TwinsUK cohort,39 a cohort of
twins of Caucasian ethnicity. We randomly selected samples from
only 1 individual of each pair of twins included in the cohort.
eGFR was calculated using the Chronic Kidney Disease Epide-
miology Collaboration Creatinine Equation.40
Assessment of CFHR3 and CFHR1 gene copy number
DNA was extracted from whole blood samples using QIAamp DNA
Blood Mini Kits (Qiagen, Hilden, Germany). Quantitative real-time
polymerase chain reaction (PCR) was performed using the ViiA
Real-Time PCR System (Applied Biosystems, Foster City, CA). Copy
number variation within the CFHR3 and CFHR1 genes was assessed
using the Taqman Copy Number Real-Time Detection System
(Applied Biosystems). Copy number variation calls were determined
using the Copy Caller Software (Applied Biosystems). Assay readings
were normalized to control samples, and the values were presented
as mean  SD. All probes were validated using genomic DNA from
healthy controls with either heterozygous or homozygous poly-
morphic deletion of the CFHR1 and CFHR3 genes. The CFHR1 gene
copy number in the renal transplant cohort was inferred from the
rs6677604 genotype, which is in linkage disequilibrium with the
CFHR1 and CFHR3 gene copy number.16 Genotyping was per-
formed using the Taqman genotyping assays (Applied Biosystems).
Measurement of serum IgA and gd-IgA levels
Serum IgA levels were measured using enzyme-linked immunosor-
bent assay (ELISA) as previously described.41 The capture antibody
was the F(ab’)2 fragment goat antihuman IgA (Jackson Immuno-
Research, West Grove, PA), and the detection antibody was the F(ab’)2
fragment biotinylated goat antihuman IgA1 (Jackson Immuno-
Research). Serum gd-IgA1 levels were measured using a lectin-based
ELISA as previously described.41 The capture antibody was a poly-
clonal rabbit antihuman IgA (Dako, Glostrup, Denmark). The
detection involvedHelix aspersa agglutinin-biotin (Sigma, Darmstadt,
Germany), followed by poly-streptavidin horseradish peroxidase
(Pierce, Waltham, MA). The intraclass correlation coefﬁcient for the
IgA assay was 0.74 (95% conﬁdence interval, 0.63–0.83), and that for
the gd-IgA1 assay was 0.89 (95% conﬁdence interval, 0.73–0.95).
Measurement of plasma fH and FHR-1 levels and serum FHR-5
levels
We used a sandwich ELISA designed by Tortajada et al. (Tortajada A,
Gutierrez E, Goicoechea de Jorge E, et al. Elevated factor H-related 1
and occurrence of factor H pathogenic variants in IgA nephropathy.
Kidney International, submitted for publication) to measure the
plasma fH and FHR-1 levels. Although FHR-1 and FHR-2 can form
homodimers, heterodimers, and heterooligomeric molecules in vivo,
the levels detected by this ELISA are referred to as FHR-1 levels
because FHR-1 is the major component in these complexes. The
capture antibody was a rabbit polyclonal antibody that recognizes
both fH and FHR-1. fH was detected with a mouse monoclonal anti-
fH antibody that recognizes SCR10 and SCR11 of fH. FHR-1 was
detected using a mouse monoclonal antibody that recognizes an
epitope within SCR1 and SCR2 of FHR-1 (both provided by Pro-
fessor Santiago Rodriguez de Cordoba, Madrid). The interassay co-
efﬁcient of variation was 8.7 for fH ELISA and 9.9 for FHR-1 ELISA.
FHR-5 levels were measured using ELISA. The capture antibody
was a rabbit monoclonal anti-FHR-5 antibody (Abcam, Cambridge,
UK). FHR-5 was detected using a mouse monoclonal anti-FHR-5
antibody (Abcam). The interassay coefﬁcient of variation was 12.1.
Statistical analysis
Normally distributed continuous variables were tested using un-
paired t-test, and pre- and posttransplant levels were compared using
paired t-test. Continuous variables with skewed distribution were
tested using Mann-Whitney U test, and conﬁdence intervals for
differences between medians were calculated using the Hodges-
Lehmann method. Categorical data was tested using chi-square test
and Fisher’s exact test (samples, <10). We applied Pearson’s corre-
lations and simple linear regression to log eGFR and FHR-1, and
Spearman’s rank correlation to eGFR and gd-IgA1. A P value <0.05
was considered to be statistically signiﬁcant. We used GraphPad
Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA)
for all analyses.
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SUPPLEMENTARY MATERIAL
Figure S1. (A) Serum IgA (left panel) and galactose-deﬁcient IgA1
(gd-IgA1; right panel) levels in patients with stable (gray dashed box)
and progressive (white dashed box) IgA nephropathy (IgAN) after
immunosuppression therapy. The progressive IgAN cohort shows
higher median serum gd-IgA1 levels. (B) Correlation of estimated
glomerular ﬁltration rate (eGFR) and serum gd-IgA1 levels in IgAN
patients (n ¼ 293). A negative correlation was calculated with Spear-
man’s rank correlation, and the black line represents the correlation
equation. (C) Comparison of serumeGFR and plasma factor H (fH) at the
same sampling point in IgAN patients (n ¼ 294) shows a small and
insigniﬁcant correlation between eGFR and plasma fH levels.
Figure S2. The plasma factor H-related protein 5 (FHR-5):factor H (fH)
ratio is not associated with IgA nephropathy (IgAN). (A) The FHR-5:fH
ratio in healthy controls and IgAN patients. We did not identify a sig-
niﬁcant difference in plasma FHR-5:fH ratio between healthy controls
(gray box) and IgANpatients (white box). (B) The FHR-5:fH ratio in stable
and progressive IgAN. Therewas no signiﬁcant difference in the plasma
FHR-5:fH ratio between patients with stable (gray boxes) and those
with progressive (white boxes) IgAN for the same CFHR1 genotype.
Table S1. Cohort characteristics for patients with IgA nephropathy
(IgAN) or autosomal dominant polycystic kidney disease (ADPKD)
who received a renal transplant. Values within parentheses represent
interquartile range. ESRD, end-stage renal disease. aP < 0.001
compared with the pretransplant levels. *rs6677604 tags the CFHR3-1
deletion.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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